Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries.
The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on 14 July 2018.
This announcement does not constitute a recommendation to shareholders or potential investors.
Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.
Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.761 as compared to the previous close of Rs. 778.75. The total number of shares traded during the day was 311848 in over 5950 trades.
The stock hit an intraday high of Rs. 790 and intraday low of 751.05. The net turnover during the day was Rs. 239086770.